Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Mycoses. 2022 Feb;65(2):152-163. doi: 10.1111/myc.13410. Epub 2021 Dec 22.
An increasing number of cases of invasive pulmonary aspergillosis (IPA) complicating influenza have been described. We performed a meta-analysis to estimate the incidence, risk factors and outcomes of IPA in patients with influenza.
A systematic search was conducted in the PubMed, EMBASE and Cochrane Library databases from their inception to 31 August 2021 for eligible studies. Data on the incidence and risk factors of and mortality due to IPA in influenza patients were pooled using a random-effects model. Sensitivity analyses restricted to severe influenza requiring intensive care unit (ICU) support and multiple subgroup analyses were performed.
Fourteen studies involving 6024 hospitalised patients with influenza were included. IPA was estimated to occur in 10% of influenza patients, with a mortality rate of 52%. Similar incidence (11%) and mortality (54%) estimates for IPA were observed in the sensitivity analysis including severe cases requiring ICU support. Subgroup analysis by geographical location showed a similar IPA rate between European (10%) and non-European (11%) studies. The IPA rate in the subset of nine studies using the modified AspICU criteria was 13%. Most subgroup analyses showed ≥50% mortality in IPA patients. Several predictors for IPA susceptibility were identified, including male sex, smoking history, chronic lung disease, influenza A (H1N1), severe conditions requiring supportive therapy, corticosteroid use before admission, solid organ transplant and haematological malignancy.
The IPA is common in individuals with severe influenza, and the prognosis is particularly poor. Influenza patients, especially those with high-risk factors, should be thoroughly screened for IPA.
越来越多的流感并发侵袭性肺曲霉病(IPA)的病例被描述。我们进行了一项荟萃分析,以评估流感患者中 IPA 的发病率、危险因素和结局。
从建库至 2021 年 8 月 31 日,我们在 PubMed、EMBASE 和 Cochrane 图书馆数据库中进行了系统检索,以确定合格的研究。使用随机效应模型汇总流感患者 IPA 的发病率、危险因素和死亡率数据。进行了敏感性分析,限制严重流感需要重症监护病房(ICU)支持,以及进行了多个亚组分析。
纳入了 14 项涉及 6024 例住院流感患者的研究。估计 10%的流感患者发生 IPA,IPA 死亡率为 52%。在包括需要 ICU 支持的严重病例的敏感性分析中,IPA 的发病率(11%)和死亡率(54%)估计值相似。按地理位置进行的亚组分析显示,欧洲(10%)和非欧洲(11%)研究的 IPA 发生率相似。在使用改良 AspICU 标准的 9 项研究的子集中,IPA 发生率为 13%。大多数亚组分析显示 IPA 患者的死亡率≥50%。确定了一些 IPA 易感性的预测因素,包括男性、吸烟史、慢性肺部疾病、甲型流感(H1N1)、需要支持治疗的严重情况、入院前使用皮质类固醇、实体器官移植和血液系统恶性肿瘤。
IPA 在严重流感患者中很常见,预后尤其不佳。流感患者,尤其是具有高危因素的患者,应彻底筛查 IPA。